Brineura

Brineura is the brand name for cerliponase alfa, an enzyme replacement therapy used to treat CLN2 disease, a form of late-infantile Batten disease. CLN2 disease is a rare, progressive neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene, leading to deficiency of the enzyme tripeptidyl peptidase 1 (TPP1). The condition typically presents in early childhood with seizures, motor and speech decline, and vision loss.

Mechanism and use. Cerliponase alfa is a recombinant form of human TPP1 that is administered directly into the brain to address the enzyme deficiency within the central nervous system. Because the disease primarily affects the brain, the drug is delivered by intraventricular infusion through an implanted CNS access device, such as an Ommaya reservoir, to the lateral ventricles. The dosing regimen is typically a fixed dose given at two-week intervals, commonly 300 units per infusion, under medical supervision.

Clinical evidence and outcomes. In clinical trials and subsequent clinical use, Brineura has been associated with stabilization or slowed progression of motor and language decline in many treated children with CLN2 disease, though it is not curative. The therapy targets neurological symptoms and aims to improve or maintain quality of life, but disease progression can continue.

Safety and monitoring. Treatment can be associated with adverse events including fever, vomiting, seizures, and device-related complications such as infections or hydrocephalus. Because administration requires brain access, careful neurosurgical and infectious disease monitoring is essential.

Regulatory status. Brineura received regulatory approval as the first approved treatment specifically for CLN2 disease, reflecting a targeted approach to a devastating pediatric neurodegenerative disorder.